Nouvelles fluoroquinolones et pneumonies aiguës communautaires (PAC)
暂无分享,去创建一个
[1] E. Varon,et al. Résistance aux antibiotiques : le modèle bêta-lactamines est-il transposable aux fluoroquinolones ? , 2002 .
[2] H. Chardon,et al. Épidémiologie de la résistance du pneumocoque aux antibiotiques , 2002 .
[3] J. Hutchinson. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. , 2002, The New England journal of medicine.
[4] L. Mandell,et al. Interspecies Recombination Contributes Minimally to Fluoroquinolone Resistance in Streptococcus pneumoniae , 2001, Antimicrobial Agents and Chemotherapy.
[5] D. Low,et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Otite Moyenne Aiguë. ANTIBIOTHERAPIE PAR VOIE GENERALE EN PRATIQUE COURANTE , 2001 .
[7] Y. Mouton,et al. Révision de la IVe Conférence de consensus en thérapeutique anti-infectieuse de la Société de pathologie infectieuse de langue française (SPILF) , 2001 .
[8] M. Fine,et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.
[9] Michael J Fine,et al. Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] L. Mandell,et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] J. Liñares,et al. Horizontal Transfer of parC and gyrA in Fluoroquinolone-Resistant Clinical Isolates ofStreptococcus pneumoniae , 2000, Antimicrobial Agents and Chemotherapy.
[12] L. Mandell,et al. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. , 2000, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.
[13] J. Liñares,et al. Fluoroquinolone resistance in Streptococcus pneumoniae. , 1999, The New England journal of medicine.
[14] L. Piroth,et al. Development of a New Experimental Model of Penicillin-ResistantStreptococcus pneumoniae Pneumonia and Amoxicillin Treatment by Reproducing Human Pharmacokinetics , 1999, Antimicrobial Agents and Chemotherapy.
[15] L. Gutmann,et al. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. , 1999, The Journal of infectious diseases.
[16] D E Low,et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.
[17] J. Justman,et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] T. Ng,et al. Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong , 1999, Antimicrobial Agents and Chemotherapy.
[19] M. R. Jacobs,et al. In Vitro Development of Resistance to Five Quinolones and Amoxicillin-Clavulanate in Streptococcus pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.
[20] L. Gutmann,et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA , 1996, Antimicrobial agents and chemotherapy.